The Best Healthcare Stocks Right Now (Updated June 2026)
These seven healthcare stocks combine recurring demand, identifiable franchises, and varying mixes of scale, profitability, and growth heading into June 2026.
Healthcare remains one of the market’s most durable themes because demand is anchored by demographics, chronic disease, and the need for ongoing treatment rather than discretionary spending cycles. That durability matters even more in a market focused on utilization trends, reimbursement pressure, and where growth is actually recurring. Recent results from major operators also show how large and economically important the sector has become, with UnitedHealthcare alone reporting $344.9 billion of revenue in 2025.
For investors, healthcare is best understood in layers: payers and providers, distributors, diagnostics, medtech, and broader branded healthcare platforms. The strongest businesses usually have clearly disclosed segments or product families tied directly to patient care, lab testing, devices, or drug distribution. That matters today because GLP-1-driven utilization, the rebound in elective procedures, and steady diagnostics demand can affect each layer differently, creating a wide spread between high-quality compounders and more speculative names.
This list focuses on seven healthcare stocks ranked by investment quality, not just by recent share-price momentum. The countdown starts with the most speculative name at No. 7 and works down to the strongest overall pick at No. 1. Along the way, the emphasis is on identifiable healthcare franchises, recurring demand, profitability, growth, and the ability to hold up under reimbursement, regulatory, and pricing pressure.
For this screen, we focused on US-listed healthcare companies with market capitalizations above $500 million and ranked them primarily on investment quality. That means weighing business durability, profitability, growth, earnings consistency, analyst sentiment, and our composite quality grades rather than chasing the fastest recent movers. The result is a countdown format: No. 7 starts with the weakest fit on this list, and the best overall healthcare stock appears at No. 1.
What they do. The company operates a consumer-first health and wellness platform that connects customers with licensed healthcare professionals across the United States and several international markets. It sells curated prescription and non-prescription products through its websites, mobile app, retail partnerships, and stores, with offerings spanning skincare, sexual health, hair care, laboratory testing, hormone health, weight loss, dermatology, and mental health.
Why it fits. Hims & Hers makes the list because it is directly tied to healthcare delivery, not just wellness branding. Its model sits at the intersection of telehealth, chronic-condition management, lab testing, and direct-to-consumer fulfillment, which aligns with the broader shift toward earlier diagnosis, outpatient care, and data-enabled treatment. The appeal is convenience and reach, but the business is still proving that it can translate scale into durable profitability.
Numbers that matter. Revenue stands at $2.37 billion, and gross margin is a strong 72.9%, showing the platform can generate attractive unit economics at the gross-profit level. But operating margin is -7.9% and net margin is -0.56%, while trailing EPS is -0.09, which explains why the stock carries a forward P/E of 58.8235 and a D+ composite quality grade. Revenue growth was 3.8% year over year, while earnings growth was -17.4%, so recent growth has not been clean. Analysts do expect EPS of 0.67 next year, but that forecast still leaves execution risk high.
Recent momentum.HIMS has beaten earnings estimates in 5 of the last 7 reported quarters, including upside surprises of 15.8% in February 2026 and 21.7% in November 2025. Still, the most recent quarter was a sharp setback: EPS came in at -0.19 versus a 0.13 estimate on May 11, 2026, a -246.2% surprise. Analyst sentiment is cautious, with 1 Buy, 6 Holds, and 1 Sell, and the average target of $26.6071 sits close to the current valuation range.
Market cap: $41.9B · Quality grade: B · Analyst consensus: Hold (avg target $181.23)
What they do. The company develops and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. Its portfolio spans Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences, covering everything from syringes and vascular access products to medication dispensing systems, microbiology diagnostics, flow cytometry tools, and surgical products.
Why it fits. Becton Dickinson is a classic healthcare infrastructure name: hospitals, labs, pharmacies, and biopharma manufacturers rely on its products every day. That makes it relevant across several of healthcare’s most durable sub-segments, especially diagnostics, medication management, specimen collection, and procedural care. The breadth is a strength, but it also means investors are buying a diversified operator rather than a single fast-growing franchise.
Numbers that matter. Revenue is $22.23 billion, with EBITDA of $6.157 billion, gross margin of 47.1%, operating margin of 14.74%, and net margin of 5.12%. Earnings growth was strong at 28.6% year over year, while revenue growth was 5.2%, suggesting margin improvement has been doing some of the heavy lifting. The stock trades at 26.534 times trailing earnings and 11.274 times forward earnings, a notable drop that points to expected EPS expansion toward 13.3978 next year. The main quality offsets are leverage and valuation sub-scores, which kept the composite grade at B rather than higher.
Recent momentum.BDX has one of the cleanest earnings records on this list, beating estimates in 7 of the last 7 quarters. The last two reports came in ahead by 4.7% in May 2026 and 3.9% in February 2026, continuing a steady pattern rather than a one-off spike. Analysts remain measured, with 1 Buy and 9 Holds, but the average target of $181.2308 implies a more constructive view than the neutral headline might suggest.
What they do. The company provides life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services worldwide. Its four segments — Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services — give it exposure to research labs, clinical diagnostics, pharmaceutical production, and vaccine and drug development.
Why it fits. Thermo Fisher fits this theme because it is one of the clearest ways to invest in recurring diagnostics, lab tools, and bioprocessing demand. Healthcare systems, clinical labs, and biopharma customers depend on its consumables, instruments, and services, which creates a broad installed base and repeat purchasing behavior. That makes it less tied to any single therapy area than many healthcare names.
Numbers that matter. Thermo Fisher generated $45.197 billion in revenue with a 15.15% profit margin, 17.89% operating margin, and 40.9% gross margin. Revenue growth was 6.2% year over year and earnings growth was 11.3%, which is solid for a company of this scale. The stock trades at 27.1766 times trailing earnings and 19.802 times forward earnings, with EPS expected to rise to 27.2628 next year from 18.18 on a trailing basis. Returns are also respectable, including 13.52% ROE and 5.0% ROA.
Recent momentum. Thermo Fisher has beaten earnings estimates in 7 straight quarters, including a 3.8% beat in April 2026 and a 5.3% beat in October 2025. The consistency matters because it suggests demand across diagnostics, instruments, and biopharma services has held up better than many investors feared. Analyst sentiment is favorable, with 7 Buys and 6 Holds, and the average target of $602.76 reflects confidence in the company’s long-term earnings power.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
What they do. The company designs and markets products and services across Biotechnology, Life Sciences, and Diagnostics. Its portfolio includes bioprocessing tools, cell culture media, chromatography resins, filtration systems, mass spectrometers, flow cytometry, genomics tools, lab automation, and clinical diagnostic instruments used by hospitals, physicians, and reference laboratories.
Why it fits. Danaher is a strong healthcare fit because it sits behind the scenes of modern diagnostics and therapeutic manufacturing. Its biotechnology and life sciences operations benefit from recurring consumables demand, while its diagnostics segment ties directly to disease detection and treatment decisions. In a healthcare market shaped by earlier diagnosis and data-enabled care, that combination is strategically attractive.
Numbers that matter. Danaher produced $24.778 billion in revenue with a 59.0% gross margin, 22.94% operating margin, and 14.89% net margin, which is one of the stronger profitability profiles on this list. Revenue growth was 3.7% year over year and earnings growth was 9.8%, showing moderate top-line expansion but better bottom-line leverage. The stock trades at 35.5678 times trailing earnings and 22.3214 times forward earnings, so investors are paying a premium for quality and expected EPS growth to 9.1013 next year from 5.16 trailing EPS. ROE of 7.08% and ROA of 4.19% are solid, though not exceptional for the valuation.
Recent momentum. Danaher has beaten estimates in 6 of the last 7 quarters, including a 6.2% beat in April 2026 and a 9.9% beat in October 2025. That pattern supports the idea that execution has been steady even in a mixed life-sciences spending environment. Analysts are constructive, with 4 Buys and 3 Holds, and the average target of $244.2727 points to continued confidence in the franchise.
What they do. The company operates across four major segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. That gives Abbott exposure to laboratory testing systems, point-of-care diagnostics, pediatric and adult nutrition, cardiovascular devices, diabetes care products, and neuromodulation devices, making it one of the broadest branded healthcare platforms in the market.
Why it fits. Abbott fits the current healthcare backdrop especially well because its revenue base is diversified across diagnostics, devices, nutrition, and pharmaceuticals. That matters in a market balancing elective-procedure recovery, ongoing chronic-disease management, and demand for earlier diagnosis. Few companies on this list have such clearly disclosed healthcare product families tied directly to recurring patient needs.
Numbers that matter. Abbott generated $45.134 billion in revenue with a 56.5% gross margin, 13.47% operating margin, and 13.9% net margin. Revenue growth was 7.8% year over year, one of the better top-line figures in this group, although earnings growth was -19.7%, showing that profit conversion has been less consistent recently. The stock trades at 25.5602 times trailing earnings and 16.6389 times forward earnings, with EPS expected to reach 6.0618 next year versus 3.57 trailing EPS. Profitability remains healthy, including 12.33% ROE and 5.59% ROA.
Recent momentum. Abbott’s earnings record is more mixed than some peers, with beats in 3 of the last 7 quarters. The latest report in April 2026 matched estimates exactly at 1.15, while January 2026 delivered a modest 0.7% beat. Analysts still lean positive overall, with 4 Buys and 7 Holds, and the average target of $117.2917 suggests the Street sees room for improvement if segment execution stays on track.
Pick #2Subscribers only
Subscribers see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
This ranking was built from a screen of US-listed healthcare companies with market capitalizations above $500 million, then ordered by investment quality. We emphasized primary-source financial data, profitability, growth, earnings consistency, analyst sentiment, and our composite quality grades, while also favoring businesses with clearly disclosed healthcare segments, products, or services. Because this list refreshes monthly, the goal is not to chase short-term price action but to identify the most durable healthcare franchises in the market right now. The countdown format matters: the strongest overall pick appears at No. 1.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
